(Total Views: 420)
Posted On: 11/06/2017 5:21:25 PM
Post# of 9144
Re: mitstevfel #3988
Scott,
That point about the 2014 Ebola case is an interesting one. It raises the question of why no one seems willing to take a chance on what to us shareholders looks like a game-changing revolutionary technology.
We've now been dealing with one of the largest med tech companies in the world for 2 years or so and yet no publicity-making large orders seem to have occurred, nor have there been any steps to acquire ownership in the company. With about 160 million or so shares, this large, multi-billion $ company could buy the entire NNLX for a measly $160 million (at $1 per share). Why is that?
I myself don't know enough about technology to make sense of this, but as a long-time long it is very frustrating to watch. Maybe we'll be able to sell some patents and fund an expansion of the N-Assay. It's been about 4 months now since the patent -for-sale announcement was made
Comments welcome.
That point about the 2014 Ebola case is an interesting one. It raises the question of why no one seems willing to take a chance on what to us shareholders looks like a game-changing revolutionary technology.
We've now been dealing with one of the largest med tech companies in the world for 2 years or so and yet no publicity-making large orders seem to have occurred, nor have there been any steps to acquire ownership in the company. With about 160 million or so shares, this large, multi-billion $ company could buy the entire NNLX for a measly $160 million (at $1 per share). Why is that?
I myself don't know enough about technology to make sense of this, but as a long-time long it is very frustrating to watch. Maybe we'll be able to sell some patents and fund an expansion of the N-Assay. It's been about 4 months now since the patent -for-sale announcement was made
Comments welcome.
(1)
(0)
